Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial

Didier M Payen, Joelle Guilhot, Yoann Launey, Anne Claire Lukaszewicz, Mahmoud Kaaki, Benoit Veber, Julien Pottecher, Olivier Joannes-Boyau, Laurent Martin-Lefevre, Matthieu Jabaudon, Olivier Mimoz, Rémi Coudroy, Martine Ferrandière, Eric Kipnis, Carlos Vela, Stéphanie Chevallier, Jihad Mallat, René Robert, ABDOMIX Group, D Payen, A C Lukaszewicz, R Robert, R Coudroy, Y Launey, N Nesseler, Y M D Mallédant, P Seguin, M Kaaki, P Beuret, B Veber, P Gouin, P G Guitard, A Lamacz, J Pottecher, O Joannes-Boyau, A Dewitte, C Fleureau, L Martin-Lefevre, J Reignier, J M Constantin, M Jabaudon, O Mimoz, H Nanadoumagar, M Ferrandière, A C Tellier, E Kipnis, M Boyer-Beyssère, C Vela, O Dematteis, S Chevallier, J P Gouello, J Mallat, D Thévenin, T Boulain, A P Dugard, B François, C Le Gall, J P Eraldi, P Rigaud, Didier M Payen, Joelle Guilhot, Yoann Launey, Anne Claire Lukaszewicz, Mahmoud Kaaki, Benoit Veber, Julien Pottecher, Olivier Joannes-Boyau, Laurent Martin-Lefevre, Matthieu Jabaudon, Olivier Mimoz, Rémi Coudroy, Martine Ferrandière, Eric Kipnis, Carlos Vela, Stéphanie Chevallier, Jihad Mallat, René Robert, ABDOMIX Group, D Payen, A C Lukaszewicz, R Robert, R Coudroy, Y Launey, N Nesseler, Y M D Mallédant, P Seguin, M Kaaki, P Beuret, B Veber, P Gouin, P G Guitard, A Lamacz, J Pottecher, O Joannes-Boyau, A Dewitte, C Fleureau, L Martin-Lefevre, J Reignier, J M Constantin, M Jabaudon, O Mimoz, H Nanadoumagar, M Ferrandière, A C Tellier, E Kipnis, M Boyer-Beyssère, C Vela, O Dematteis, S Chevallier, J P Gouello, J Mallat, D Thévenin, T Boulain, A P Dugard, B François, C Le Gall, J P Eraldi, P Rigaud

Abstract

Purpose: To test whether the polymyxin B hemoperfusion (PMX HP) fiber column reduces mortality and organ failure in peritonitis-induced septic shock (SS) from abdominal infections.

Method: Prospective, multicenter, randomized controlled trial in 18 French intensive care units from October 2010 to March 2013, enrolling 243 patients with SS within 12 h after emergency surgery for peritonitis related to organ perforation. The PMX HP group received conventional therapy plus two sessions of PMX HP. Primary outcome was mortality on day 28; secondary outcomes were mortality on day 90 and a reduction in the severity of organ failures based on Sequential Organ Failure Assessment (SOFA) scores.

Primary outcome: day 28 mortality in the PMX HP group (n = 119) was 27.7 versus 19.5% in the conventional group (n = 113), p = 0.14 (OR 1.5872, 95% CI 0.8583-2.935). Secondary endpoints: mortality rate at day 90 was 33.6% in PMX-HP versus 24% in conventional groups, p = 0.10 (OR 1.6128, 95% CI 0.9067-2.8685); reduction in SOFA score from day 0 to day 7 was -5 (-11 to 6) in PMX-HP versus -5 (-11 to 9), p = 0.78. Comparable results were observed in the predefined subgroups (presence of comorbidity; adequacy of surgery, <2 sessions of hemoperfusion) and for SOFA reduction from day 0 to day 3.

Conclusion: This multicenter randomized controlled study demonstrated a non-significant increase in mortality and no improvement in organ failure with PMX HP treatment compared to conventional treatment of peritonitis-induced SS.

Trial registration: ClinicalTrials.gov NCT01222663.

Figures

Fig. 1
Fig. 1
Protocol design of the trial from the surgery until the second session of hemoperfusion
Fig. 2
Fig. 2
Flow chart of the study
Fig. 3
Fig. 3
Cumulative incidence of death overtime in the two arms: HP-PMX (continuous line) and standard treatment (hashed line). No significant difference was observed (p = 0.1067)

References

    1. Liu V, Escobar GJ, Greene JD, Soule J, Whippy A, Angus DC, Iwashyna TJ. Hospital deaths in patients with sepsis from 2 independent cohorts. JAMA. 2014;312:90–92. doi: 10.1001/jama.2014.5804.
    1. Koperna T, Schulz F. Prognosis and treatment of peritonitis. Do we need new scoring systems? Arch Surg. 1996;131:180–186. doi: 10.1001/archsurg.1996.01430140070019.
    1. Riche FC, Dray X, Laisne MJ, Mateo J, Raskine L, Sanson-Le Pors MJ, Payen D, Valleur P, Cholley BP. Factors associated with septic shock and mortality in generalized peritonitis: comparison between community-acquired and postoperative peritonitis. Crit Care. 2009;13:R99. doi: 10.1186/cc7931.
    1. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, Jauregui L, Krell K, Pachl J, Takahashi T, Peckelsen C, Cordasco E, Chang CS, Oeyen S, Aikawa N, Maruyama T, Schein R, Kalil AC, Van Nuffelen M, Lynn M, Rossignol DP, Gogate J, Roberts MB, Wheeler JL, Vincent JL. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA. 2013;309:1154–1162. doi: 10.1001/jama.2013.2194.
    1. Losser MR, Bernard C, Beaudeux JL, Pison C, Payen D. Glucose modulates hemodynamic, metabolic, and inflammatory responses to lipopolysaccharide in rabbits. J Appl Physiol. 1997;83:1566–1574.
    1. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, Miller-Graziano C, Moldawer LL, Mindrinos MN, Davis RW, Tompkins RG, Lowry SF. A network-based analysis of systemic inflammation in humans. Nature. 2005;437:1032–1037. doi: 10.1038/nature03985.
    1. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med. 1994;121:1–5. doi: 10.7326/0003-4819-121-1-199407010-00001.
    1. Joannes-Boyau O, Honore PM, Perez P, Bagshaw SM, Grand H, Canivet JL, Dewitte A, Flamens C, Pujol W, Grandoulier AS, Fleureau C, Jacobs R, Broux C, Floch H, Branchard O, Franck S, Roze H, Collin V, Boer W, Calderon J, Gauche B, Spapen HD, Janvier G, Ouattara A. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med. 2013;39:1535–1546. doi: 10.1007/s00134-013-2967-z.
    1. Payen D, Mateo J, Cavaillon JM, Fraisse F, Floriot C, Vicaut E, Hemofiltration, Sepsis Group of the College National de Reanimation et de Medecine d’Urgence des Hopitaux e-U Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med. 2009;37:803–810. doi: 10.1097/CCM.0b013e3181962316.
    1. Vincent JL, Laterre PF, Cohen J, Burchardi H, Bruining H, Lerma FA, Wittebole X, De Backer D, Brett S, Marzo D, Nakamura H, John S. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock. 2005;23:400–405. doi: 10.1097/01.shk.0000159930.87737.8a.
    1. Nakamura T, Ebihara I, Shoji H, Ushiyama C, Suzuki S, Koide H. Treatment with polymyxin B-immobilized fiber reduces platelet activation in septic shock patients: decrease in plasma levels of soluble P-selectin, platelet factor 4 and beta-thromboglobulin. Inflamm Res. 1999;48:171–175. doi: 10.1007/s000110050442.
    1. Nakamura T, Kawagoe Y, Suzuki T, Shoji H, Ueda Y, Koide H. Polymyxin B-immobilized fiber hemoperfusion with the PMX-05R column in elderly patients suffering from septic shock. Am J Med Sci. 2007;334:244–247. doi: 10.1097/MAJ.0b013e3180a5e8d8.
    1. Nemoto H, Nakamoto H, Okada H, Sugahara S, Moriwaki K, Arai M, Kanno Y, Suzuki H. Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis. Blood Purif. 2001;19:361–368. doi: 10.1159/000046966.
    1. Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin) Ther Apher Dial. 2003;7:108–114. doi: 10.1046/j.1526-0968.2003.00005.x.
    1. Suzuki H, Nemoto H, Nakamoto H, Okada H, Sugahara S, Kanno Y, Moriwaki K. Continuous hemodiafiltration with polymyxin-B immobilized fiber is effective in patients with sepsis syndrome and acute renal failure. Ther Apher. 2002;6:234–240. doi: 10.1046/j.1526-0968.2002.00416.x.
    1. Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, Lentini P, Nalesso F, Ueno T, Ranieri VM, Ronco C. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11:R47. doi: 10.1186/cc5780.
    1. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, Rottoli F, Giunta F, Ronco C. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301:2445–2452. doi: 10.1001/jama.2009.856.
    1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, International Sepsis Definitions C 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med. 2003;29:530–538. doi: 10.1007/s00134-003-1662-x.
    1. Scheller J, Garbers C, Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol. 2014;26:2–12. doi: 10.1016/j.smim.2013.11.002.
    1. Wacha H, Hau T, Dittmer R, Ohmann C. Risk factors associated with intraabdominal infections: a prospective multicenter study. Peritonitis Study Group. Langenbecks Arch Surg. 1999;384:24–32. doi: 10.1007/s004230050169.
    1. Iwagami M, Yasunaga H, Doi K, Horiguchi H, Fushimi K, Matsubara T, Yahagi N, Noiri E. Postoperative polymyxin B hemoperfusion and mortality in patients with abdominal septic shock: a propensity-matched analysis. Crit Care Med. 2014;42:1187–1193. doi: 10.1097/CCM.0000000000000150.
    1. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD, Group P-SS Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055–2064. doi: 10.1056/NEJMoa1202290.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner